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background. The International Nosocomial Infection Control Consortium (INICC) was established in 15 developing countries to
reduce infection rates in resource-limited hospitals by focusing on education and feedback of outcome surveillance (infection rates) and
process surveillance (adherence to infection control measures). We report a time-sequence analysis of the effectiveness of this approach in
reducing rates of central line–associated bloodstream infection (CLABSI) and associated deaths in 86 intensive care units with a minimum
of 6-month INICC membership.
methods. Pooled CLABSI rates during the first 3 months (baseline) were compared with rates at 6-month intervals during the first 24
months in 53,719 patients (190,905 central line–days). Process surveillance results at baseline were compared with intervention period data.
results. During the first 6 months, CLABSI incidence decreased by 33% (from 14.5 to 9.7 CLABSIs per 1,000 central line–days). Over
the first 24 months there was a cumulative reduction from baseline of 54% (from 16.0 to 7.4 CLABSIs per 1,000 central line–days; relative
risk, 0.46 [95% confidence interval, 0.33–0.63]; ). The number of deaths in patients with CLABSI decreased by 58%. During theP ! .001
intervention period, hand hygiene adherence improved from 50% to 60% ( ); the percentage of intensive care units that usedP ! .001
maximal sterile barriers at insertion increased from 45% to 85% ( ), that adopted chlorhexidine for antisepsis increased from 7%P ! .001
to 27% ( ), and that sought to remove unneeded catheters increased from 37% to 83% ( ); and the duration of centralPp .018 Pp .004
line placement decreased from 4.1 to 3.5 days ( ).P ! .001
conclusions. Education, performance feedback, and outcome and process surveillance of CLABSI rates significantly improved infection
control adherence, reducing the CLABSI incidence by 54% and the number of CLABSI-associated deaths by 58% in INICC hospitals during
the first 2 years.
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Healthcare-associated infections from invasive medical de-
vices in the intensive care unit (ICU)—particularly central
line–associated bloodstream infection (CLABSI), ventilator-
associated pneumonia, and catheter-associated urinary tract
infection—have been shown to pose the greatest threat to
patient safety.1,2 Over the past decade, studies done in the
industrialized Western countries have shown that a systematic
institutional approach that assures a very high level of ad-
herence to essential infection control practices has brought
striking reductions in the incidence of CLABSI in patients in
an ICU.3,4
In 2002, we established an International Nosocomial In-
fection Control Consortium (INICC) in countries of the de-
veloping world and found that rates of device-associated in-
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fection in the ICUs of the hospitals of these countries, which
have very limited resources, are 3–5 times higher than rates
in North American ICUs.5-7 Because of the resource limita-
tions, we have focused our efforts to reduce the incidence of
device-associated infection in these hospitals on education,
outcome surveillance (rates of device-associated infection),
process surveillance (adherence to hand hygiene and other
basic infection control practices shown to reduce the inci-
dence of device-associated infection), and performance feed-
back of each ICU’s surveillance data to the healthcare per-
sonnel working in that unit.8 We report a time-sequence
analysis of the efficacy of this approach on controlling CLAB-
SIs in 86 ICUs that have been members of the consortium
for at least 6 months.
methods
Background on INICC
INICC is an international nonprofit, open, multicenter, col-
laborative healthcare-associated infection control program
with a surveillance system based on that of the US National
Healthcare Safety Network9,10 (NHSN; formerly the National
Nosocomial Infection Surveillance [NNIS] system), and it is
the first multinational research network established to control
healthcareassociated infections in hospitals through the
analysis of data collected on a voluntary basis by its member
hospitals. Gaining new members each month, INICC now
comprises a dynamic network of almost 300 ICUs in ap-
proximately 40 countries from 4 continents, and at the pres-
ent time it is the only source of aggregate standardized in-
ternational data on healthcare-associated infection in the de-
veloping world.5-7,11-24
From its inception, the consortium has focused on sur-
veillance and control of device-associated infection in the
ICU, the healthcare setting with the most vulnerable patients
with the heaviest exposure to invasive devices and highest
rates of nosocomial infection.9 INICC has employed the sur-
veillance methods and definitions for healthcare-associated
infection developed by the Centers for Disease Control and
Prevention’s long-standing NNIS/NHSN program in US hos-
pitals10 and has vigorously promoted the consistent imple-
mentation of simple, inexpensive, evidence-based measures
for prevention of healthcare-associated infection.5-8
The limited knowledge regarding healthcare-associated in-
fection worldwide, especially in developing countries, the
need for more precise measurement of risk and outcomes in
individual patient groups, and recognition of the importance
of surveillance,25 especially feedback of surveillance data, to an
effective infection control program led from the outset to the
development and implementation of the 2 INICC surveillance
components, outcome surveillance and process surveillance.8
Outcome surveillance includes rates of CLABSI, ventilator-
associated pneumonia, and catheter-associated urinary tract
infection per 1,000 device-days. Process surveillance includes
rates of adherence to hand hygiene and selected infection
control measures for prevention of vascular catheter–related
bloodstream infection, catheter-associated urinary tract in-
fection, and ventilator-associated pneumonia.8
Process surveillance is designed to monitor adherence to
easily measurable, important control steps, such as hand hy-
giene, and is limited at this time by the resources available
in the member hospitals. Hand hygiene adherence by health-
care workers, based on the frequency with which hand hy-
giene is performed when clearly indicated, is monitored by
the hospital infection control practitioner during randomly
selected 1-hour observation periods 3 times perweek; health-
care workers are aware that hand hygiene practices are mon-
itored but are not informed of when the observations are
taking place. Adherence to vascular catheter care is also mon-
itored and recorded 5 days per week: hand hygiene before
and after catheter insertion or redressing a vascular catheter;
the presence of a sterile gauze or polyurethane dressing on
the insertion site; recording of the date of catheter insertion
and last administration set change; replacement of the gauze
dressing every 48 hours and transparent semipermeable
membrane dressings at least every 7 days, with the date and
time of the dressing change recorded; replacement of pe-
ripheral venous catheters within 72 hours; and replacement
of the administration set every 72 hours. Striving to limit
catheter placements in the femoral vein, use of maximal sterile
barrier precautions during the insertion procedure, disinfec-
tion of the insertion site with 2%–4% chlorhexidine, and
prompt removal of catheters when they are no longer needed
have not yet been incorporated into formal process surveil-
lance; however, they are vigorously promulgated in the INICC
ICUs.
Targeted Use of Surveillance Data as a Control Measure
The concept of using performance feedback of outcome sur-
veillance and process surveillance as a valuable control mea-
sure in hospitals with limited resources was based on its
proven effectiveness in studies within individual Argentine
hospitals before the establishment of INICC as an interna-
tional network in 2002.26-28 On a monthly basis, the INICC
Headquarters team prepares and sends to each participating
hospital a final report on their institutional rates of device-
associated infection, bacterial profile, bacterial resistance,
length of stay, and mortality in their ICU(s) and their ad-
herence to hand hygiene, central line and urinary catheter
care, and measures to prevent ventilator-associated pneu-
monia. To provide feedback to ICU staff in the unit, charts
providing a running tally of rates of device-associated infec-
tions compiled by the infection control practitioner and the
INICC Headquarters Team are reviewed at monthly staff
meetings and posted in a prominent location in the ICU.8
Definitions
Laboratory-confirmed CLABSI. If CLABSI is suspected, the
central venous line is removed aseptically and the distal 5 cm
of the catheter is amputated and cultured, using the stan-
dardized semiquantitative method.29 Concomitant blood sam-
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table 1. Characteristics of the Participating In-
tensive Care Units (ICUs)
Characteristic No. of ICUs
Location
Argentina 15
Turkey 14
Colombia 13
India 13
Mexico 7
Philippines 6
Brazil 5
Peru 5
El Salvador 2
Costa Rica 1
Cuba 1
Lebanon 1
Macedonia 1
Morocco 1
Panama 1
Type of hospitala
Academic teaching 26
Private community 16
Public 15
Type of ICU
Medical-surgical 51
Pediatric 6
Newborn 9
Coronary 8
Burn 1
Surgical 4
Neurosurgical 3
Medical 3
Trauma 1
a By type of hospital, 46% of the ICUs were in academic
teaching hospitals, 28% were in private community hos-
pitals, and 26% were in public hospitals.
ples for culture are drawn percutaneously in most cases.
In each hospital, standard laboratory methods are used to
identify microorganisms, and standardized susceptibility test-
ing is performed.
Our definition of a laboratory-confirmed CLABSI requires
that a patient with a central line has a recognized pathogen
isolated from 1 or more percutaneous blood cultures after
48 hours of catheterization, that the pathogen cultured from
the blood is not related to an infection at another site, and
that the patient has 1 or more of the following signs or
symptoms: fever (temperature, at least 38C), chills, or hy-
potension. With skin commensals (diphtheroids, Bacillus spe-
cies, Propionibacterium species, or coagulase-negative staph-
ylococci or micrococci), the organism has been recovered
from 2 or more separate blood cultures.10
Clinically suspected CLABSI. Our definition of a clinically
suspected CLABSI requires a patient with a central line who
has at least 1 of the following clinical signs, with no other
recognized cause: fever (temperature, at least 38C), hypo-
tension (systolic blood pressure less than or equal to 90 mm
Hg), or oliguria (less than or equal to 20 mL/hr), but either
blood cultures were not obtained or no organisms were re-
covered from blood cultures; there is no apparent infection
at another site; and the physician institutes antimicrobial
therapy.10
Data Analysis
The time-sequence analysis of INICC data on CLABSI was
restricted to hospitals that were active members of the con-
sortium through December 31, 2008, and had submitted
monthly surveillance data for at least 6 months. Rates of
CLABSI and deaths in patients with CLABSI during months
5–7, 11–13, 17–19, and 23–25 were compared with rates in
the baseline period, months 1–3, for the cohort of ICUs rep-
resented in each intervention period analyzed. The baseline
rate of each time cohort was unique. Trends in process sur-
veillance for hand hygiene and vascular catheter care, as re-
ported monthly, and representative infection control practices
within each ICU, based on periodic surveys, over the inter-
vention period were also summarized.
Statistical Methods
The aggregate characteristics of all patients hospitalized dur-
ing the baseline period and during the last 3 months of the
intervention period in each hospital were compared using the
Fisher exact test for dichotomous variables and the un-
matched Student t test for continuous variables. Relative risk
(RR) ratios with 95% confidence intervals (CIs) were cal-
culated for comparison of rates of CLABSI and CLABSI-
associated all-cause ICU mortality at baseline and subsequent
intervention periods, using the baseline data appropriate to
each cohort. P values less than .05 by 2-sided tests were con-
sidered to be significant.
results
Patient Population
During the first 8 years of INICC, 2002–2009, 86 ICUs in 15
countries participated in INICC for at least 6 months; the
countries, the types of hospitals, and the types of ICUs rep-
resented are summarized in Table 1. During the baseline pe-
riod, 7,751 patients were hospitalized in 86 member ICUs
(30,889 central line–days); during the intervention period,
there were 45,968 patients (160,016 central line–days). The
characteristics of patients during the baseline period and the
intervention period were very similar, including Average Se-
verity of Illness Scores5 (Table 2).
Process Surveillance and Changes in Practice
Representative infection control practices in the member
ICUs and the results of process surveillance during the base-
line period and during the intervention period in each hos-
pital are shown in Table 3. Adherence to hand hygiene im-
proved significantly, from 50% to 60% ( ). The per-Pp .001
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table 2. Characteristics of Patients at Baseline and During the Intervention Period
Characteristic Baseline Intervention RR (95% CI) P
No. of patients 7,751 45,968 …
No. of central line–days 30,889 160,016 …
Age, mean (IQR), years 53.6 (40– 70) 55.7 (42– 72) …
Sex, no. (%) of patients
Male 4,756 (61) 27,603 (60) 0.98 (0.95–1.01) .169
Female 2,995 (39) 18,365 (40) 1.03 (0.99–1.07) .090
Service, no. (%) of patients
Adult 6,247 (81) 41,540 (90) …
Pediatric 430 (6) 1,459 (3) …
Neonatal 874 (11) 2,966 (6) …
ASIS, mean (IQR) 2.96 (2–4) 2.91 (2–4) … .806
Underlying diseases, no. (%) of patients
Cardiac surgery 228 (3) 1,464 (3) 1.00 (0.87–1.15) .967
Cancer 205 (3) 1,320 (3) 1.00 (0.86–1.16) .999
Abdominal surgery 323 (4) 1,882 (4) 0.90 (0.80–1.02) .096
Thoracic surgery 43 (1) 212 (0.5) 0.77 (0.55–1.106) .109
Trauma 188 (2) 1,111 (2) 0.92 (0.79–1.07) .276
note. ASIS, Average Severity of Illness Score; CI, confidence interval; IQR, interquartile range; RR, relative risk.
centage of ICUs starting to consistently use maximal sterile
barriers at catheter insertion rose from 46% to 85% (Pp
), the percentage adopting chlorhexidine for insertion site.017
antisepsis rose from 7% to 27% ( ), and the per-Pp .018
centage making proactive efforts to promptly remove un-
needed catheters rose from 37% to 83% ( ); the meanPp .004
duration of central line placement decreased from 4.1 to 3.5
days ( ).Pp .001
CLABSIs
The overall baseline rate of CLABSI in the 86 ICUs was 14.5
per 1,000 central line–days, with a higher rate among the
earliest members of the consortium and a modest decrease
in the baseline rate among hospitals that have joined most
recently (Table 3). By the time hospitals had been members
of INICC for 6 months (86 ICUs), the incidence of CLABSI
had decreased 33% relative to their baseline period (14.5 vs
9.7 CLABSIs per 1,000 central line–days; RR, 0.67 [95% CI,
0.58–0.77]; ), which was sustained at 12 months (10.0P ! .001
CLABSIs per 1,000 central line–days) and 18 months (9.8
CLABSIs per 1,000 central line–days); however, by 24 months,
there was a further decrease, yielding a cumulative reduction
from baseline of 54% (16.0 vs 7.4 CLABSIs per 1,000 central
line–days; RR, 0.46 [95% CI, 0.33–0.63]; ).P ! .001
CLABSI-Associated Mortality
During the 24-month intervention period, all-cause deaths
in patients with CLABSI decreased commensurately, reaching
a 58% decrease by 24 months (Table 4).
discussion
Percutaneously inserted, short-term, noncuffed, and nontun-
nelled central venous lines are widely used in patient care
around the world, most often in critically ill patients who
have sustained major trauma, who have undergone extensive
surgery, or who are critically ill with sepsis or organ failure.
The most frequent life-threatening complication of central
venous access is CLABSI,5,6,9 which is associated with major
morbidity, prolongation of hospitalization, excess hospital
costs ranging in developing countries from US$5,000 to
$14,000 per episode, and significant attributable mortality.30,31
Nearly two-thirds of all nosocomial bloodstream infections
in US ICUs are CLABSIs.32
Federal governments have become very interested in en-
hancing the safety of central venous access. In 2007 the US
Congress passed legislation denying federal reimbursement
for the incremental healthcare costs of CLABSIs.33 A number
of recent prospective studies in the Western industrialized
countries have shown that hospitals that take a highly or-
ganized, multidisciplinary, systematic approach to the man-
agement of central lines have reported striking reductions in
the incidence of CLABSI in ICUs.3,4 This systematic approach
starts with formal training of all personnel who insert and
care for central venous catheters and focuses on limiting the
number of femoral site insertions, uniform use of maximal
sterile barriers during catheter insertion, disinfecting catheter
insertion sites with tincture of chlorhexidine rather than io-
dine-based antiseptics, promptly removing unneeded cathe-
ters, and providing feedback of CLABSI rates.
We have previously shown5,6 and reaffirm in this report
that ICUs in developing countries have rates of CLABSI, ven-
tilator-associated pneumonia, and catheter-associated urinary
tract infection that are 3–5 times higher than rates reported
from North American ICUs. Most resource-limited coun-
tries do not have laws mandating healthcareassociated infec-
tion control programs, and hospital accreditation is rarely re-
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table 3. Representative Infection Control Practices and the Results of Process Surveillance
Variable Baseline Intervention RR (95% CI) P
Representative infection control practice
Hand hygiene practices
Hand washing with soap and water 76 44 0.58 (0.34–0.99) .043
Alcohol-based hand rub 20 66 3.37 (1.60–7.08) .001
Hand washing with povidone-iodine 20 39 1.96 (0.88–4.36) .094
Hand washing with CHG 23 53 2.27 (1.12–4.62) .020
Hospital intravenous team 13 26 2.00 (0.75–5.33) .157
Femoral lines frequent 9 9 1.00 (0.25–4.00) 1.99
Use of maximal sterile barriers at
catheter insertion
46 85 1.86 (1.11–3.13) .017
Cutaneous antisepsis with CHG 7 27 4.09 (1.15–4.49) .018
Insertion site dressing
None 32 12 0.37 (0.13–1.04) .050
Nonsterile dressing 37 5 0.13 (0.03–0.57) .001
Sterile gauze 57 76 1.32 (0.79–3.63) .071
Sterile transparent dressing 28 52 1.85 (0.94–3.63) .071
Topical antibiotic on insertion sites 2 0 … .322
Intravenous container vented with a needle 63 36 0.58 (0.32–1.05) .068
Scheduled replacement of central lines 69 29 0.43 (0.41–0.45) !.001
Proactive efforts to promptly remove
unneeded catheters
37 83 2.25 (1.27–3.97) .004
3-way stopcocks used widely 94 88 0.94 (0.62–1.41) .756
Special technologies
Antimicrobial-coated central catheters 6 4 0.68 (0.11–4.07) .671
CHG sponge dressings 2 8 4.08 (0.46–6.52) .172
Results of process surveillance
Adherence to hand hygiene,a % 50b 60c 1.21 (1.18–1.24) .001
Central line usage,d % 53e 52f 0.99 (0.98–1.01) .120
Duration of central line usage,
mean (IQR), days
4.1 (0–5) 3.5 (0–4) 0.85 (…) .001
Sterile dressing, in good condition 81 82 1.01 (0.99–1.01) .669
Administration set replaced every
72–96 hours, %
18 50 2.73 (2.52–2.96) .001
note. Data are % of opportunities, unless otherwise indicated. CHG, chlorhexidine gluconate; CI, confidence
interval; IQR, interquartile range; IV, intravenous; RR, relative risk.
a No. of times hand hygiene performed / no. of opportunities where indicated, during random periods of process
surveillance.
b 7,831/15,728.
c 48,574/80,557.
d No. of central line–days / no. of patient-days.
e 30,889/58,742.
f 160,016/306,340.
quired. Funds and resources for infection control are very
limited, nurse-to-patient staffing ratios are far lower on av-
erage than in ICUs of the developed countries, and there are
larger proportions of inexperienced nurses, all of which have
been shown to have a powerful association with increased
risks of device-associated infection.34 Finally, the use of out-
dated technology also may be a factor. For example, open
intravenous infusion systems that in developing countries
appear to be associated with a substantially increased risk of
infusion-associated bloodstream infection35 are used almost
universally in resource-limited countries instead of the closed
intravenous systems that are the standard of care in most
developed countries. Measures considered to be mandatory
in US ICUs—oversight of the entire catheter insertion pro-
cedure by an ICU nurse who is following a checklist and who
is empowered to stop the procedure if a break in protocol is
detected, maximal sterile barrier precautions during catheter
insertion, and routine use of 2% tincture of chlorhexidine
for cutaneous antisepsis4—have been untenable in the hos-
pitals of most developing countries.
We believe there is a moral imperative to bring current
knowledge of the epidemiology and control of healthcare-
associated infection to the many thousands of hospitals and
millions of patients of the developing world, and we believe
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table 4. Deaths in Patients with Central Line–Associated Bloodstream Infection (CLABSI)
during Baseline and Intervention Periods
Cohort
No. of
ICUs
No. of
patients
at risk
CLABSI-associated
deaths
RRa (95% CI) PNo.
No. per 100
patients, %
Months 1–3 (baseline) 86 7,376 77 1.04 Reference
Months 5–7 86 7,522 46 0.61 0.59 (0.41–0.84) .004
Months 11–13 68 4,718 22 0.47 0.45 (0.28–0.72) .001
Months 17–19 43 3,527 16 0.45 0.43 (0.25–0.74) .002
Months 23–25 28 2,264 10 0.44 0.42 (0.22–0.82) .008
note. CI, confidence interval; RR, relative risk.
a All periods compared with the first 3 months (baseline).
table 5. Comparison of Rates of Central Line–Associated Bloodstream Infection (CLABSI) during Baseline (Months 1–3) and Inter-
vention Periods
Cohort
No. of
ICUs
No. of CLABSIs /
no. of central line–days
No. of CLABSIs per
1,000 central line–days
RRa (95% CI) PBaseline Intervention Baseline (95% CI) Intervention (95% CI)
Baseline to months 5–7 86 447/30,889 290/30,026 14.5 (13.2–15.9) 9.7 (8.6–10.8) 0.67 (0.58–0.77) .001
Baseline to months 11–13 68 325/19,981 146/14,516 16.3 (14.6–18.1) 10.1 (8.5–11.8) 0.62 (0.51–0.75) .001
Baseline to months 17–19 43 207/12,214 108/11,029 16.9 (14.7–19.4) 9.8 (8.0–11.8) 0.58 (0.46–0.73) .001
Baseline to months 23–25 28 134/8,378 53/7,206 16.0 (13.4–18.9) 7.4 (5.5–9.6) 0.46 (0.33–0.63) .001
note. CI, confidence interval; RR, relative risk.
a All periods are compared with baseline.
that INICC provides a unique opportunity to move rapidly
toward achieving this goal. In this study in a large and diverse
patient population of nearly 60,000 patients hospitalized in
86 ICUs of 15 developing countries around the world, we
have shown that certain steps were followed by very sub-
stantial improvements in process indicators—most notably
in hand hygiene, maximal barrier precautions during the in-
sertion procedure, and limiting the duration of catheteriza-
tion (Table 2). These steps were as follows: (1) providing
basic education in hospital epidemiology and infection con-
trol (accomplished by a single infection control practition-
er in nearly every hospital), (2) conducting surveillance of
CLABSI and process surveillance, and (3) providing contin-
uous performance feedback in each ICU. The improvements
were paralleled by a 33% decrease in CLABSIs by 5–7 months
and a 54% decrease in CLABSIs by 23–25 months of active
participation in INICC (Table 5).
The concept of providing continuous feedback to industrial
workers of the results of monitoring of the quality of the
final product to improve the efficiency of production and
product quality stems from the epochal contributions of
Deming36 and others in the industrial engineering movement
following World War II, and it was given even greater traction
by the more recent Six Sigma movement in American in-
dustry.37 The first attempt to apply industrial engineering to
prevent hospital-acquired infections followed the establish-
ment of the NNIS program by the Centers for Disease Control
and Prevention in 1969.38 Hospitals participating in that nas-
cent program were expected to communicate the results of
surveillance of nosocomial infections to physicians, nurses,
and hospital administrators with the expectation that these
data would fuel efforts to improve adherence to basic infec-
tion control practices being promulgated at the time and
ultimately would reduce the incidence of nosocomial infec-
tions in patients. Mandated by the Joint Commission on
Accreditation of Hospitals in the early 1970s, surveillance of
nosocomial infections rapidly became a basic feature of all
US hospital infection control programs, and rates of infection
decreased modestly but progressively over the decades. From
its inception,5,6,26-28 INICC has brought the use of feedback
of surveillance data as a simple but powerful strategy to im-
prove quality in healthcare to a new level, monitoring and
providing continuous feedback not only of outcome data
(rates of nosocomial infection) but also of the results of pro-
cess surveillance (rates of adherence to hand hygiene and
other simple but effective evidence-based infection control
practices) (Table 2). Also, INICC has shown that combining
education with feedback of both outcome and process sur-
veillance can bring quantum reductions in the incidence of
CLABSI in ICUs (Table 5) as well as deaths associated with
CLABSI (Table 4).9,25 Recently, other countries have also suc-
cessfully applied feedback of infection surveillance data to
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achieve significant reductions in rates of nosocomial
infection.39,40 The hospitals of developed industrialized coun-
tries might consider adding process surveillance and its feed-
back to their current use of surveillance data on nosocomial
infection rates.
Because risk factors for nosocomial bacteremia were com-
parable during the 2 phases of this time-sequence analysis
(Table 2), our study has limitations. Because the individual
participating ICUs were not concurrently randomized to par-
ticipate in INICC or to not participate (control subjects), we
cannot exclude the possibility that the observed decrease in
CLABSIs after joining INICC simply represented a sponta-
neous downward trend in the incidence of CLABSI in most
or all ICUs over the study period, unrelated to the activities
of the institutional infection control practitioner and the con-
tinuous feedback of institutional data from the central INICC
office. We think this is unlikely because there has been only
a modest decrease in the baseline rate of CLABSI in new
hospitals joining INICC over the tenure of the program to
date, far less than the striking reductions seen in each cohort
analyzed over the first 24-month intervention period. Sec-
ondly, the study design does not permit accurate determi-
nation of the epidemiologic mechanisms responsible for the
striking decrease in CLABSIs during the intervention pe-
riod—that is, was it due to education or to targeted perfor-
mance feedback of surveillance data? If it was due to per-
formance feedback, which had the greater impact, outcome
surveillance or process surveillance? If process surveillance
had the greater feedback, which data had the greatest influ-
ence on practice?
In summary, although the magnitude of reduction in the
INICC hospitals achieved to date is gratifying, rates of
CLABSI in the range of 7 cases per 1,000 central line–days
are still too high, but we believe greater reductions are achiev-
able. Our immediate goals are to enhance and to strengthen
the simple surveillance and performance feedback program
that has proven effective to date and to find ways to assure
that maximum sterile barrier precautions are used for every
central line insertion, femoral vein insertions are reduced to
a minimum, 2% chlorhexidine is made available in every
hospital and used for all catheter insertions, 3-way stopcocks
are replaced by closed connectors, and systems are established
to assure immediate removal of central catheters that are no
longer necessary— ideally, to incorporate as many of these
key measures as feasible into ongoing process surveillance.
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